Sources say the firm had to act to calm Japanese investors, restive at the flow of bad news.
The company is working on a synergy plan with Ranbaxy under which Daiichi Sankyo's product will be introduced in emerging markets through Ranbaxy, he said, declining to give further details.
Company is among the few companies in the sector getting pulled up by FDA for violations at its factories in India.
